Patients with chronic spontaneous urticaria improved early, with benefits lasting through the 52-week follow-up for those who ...

In September 2024, the FDA approved a new biosimilar for treating retinal conditions, marking a significant development in ...

Among biopharma firms, size didn’t always correlate with the highest wages, a recently debuted analysis of ‘best’ pharma ...

As part of its extensive offerings for the eczema community throughout October, NEA hosts The Ecz-hibition, a social ...

On August 23, 2024, the FDA approved Amgen’s aflibercept biosimilar PAVBLU (aflibercept-ayyh), a biosimilar of Regeneron’s EYLEA®. According to the approval letter, “Pavblu is indicated for ...

Adding daratumumab to lenalidomide in maintenance therapy for multiple myeloma significantly reduced rates of minimal ...

Regeneron Pharmaceuticals (REGN) and Sanofi (SNY) announced that the National Medical Products Administration in China has ...

Regeneron Pharmaceuticals Inc. shares are headed for their biggest monthly drop since mid-2022 after a legal setback that ...

Dupixent is the first biologic medicine approved in the U.S. for the common lung condition, though competitors from GSK, AstraZeneca and Roche could follow.

After more than a decade without any therapeutic advancements in chronic obstructive pulmonary disorder (COPD), people with ...

Sanofi and Regeneron’s Dupixent is gearing up to expand its reach ... compared with placebo. AstraZeneca and Amgen are also planning a Phase III for Tezspire in COPD.